NASDAQ:APLT Applied Therapeutics (APLT) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free APLT Stock Alerts $4.83 -0.32 (-6.21%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$4.65▼$5.2350-Day Range$2.68▼$7.4052-Week Range$0.85▼$9.39Volume859,052 shsAverage Volume1.99 million shsMarket Capitalization$511.45 millionP/E RatioN/ADividend YieldN/APrice Target$11.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Applied Therapeutics alerts: Email Address Applied Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside140.2% Upside$11.60 Price TargetShort InterestHealthy4.70% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.51Based on 8 Articles This WeekInsider TradingSelling Shares$2.47 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.53) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.74 out of 5 starsMedical Sector56th out of 914 stocksBiotechnology Industry3rd out of 54 stocks 4.5 Analyst's Opinion Consensus RatingApplied Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApplied Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.70% of the outstanding shares of Applied Therapeutics have been sold short.Short Interest Ratio / Days to CoverApplied Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Applied Therapeutics has recently increased by 31.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApplied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Applied Therapeutics is -0.88. Previous Next 2.5 News and Social Media Coverage News SentimentApplied Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Applied Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,469,181.00 in company stock.Percentage Held by Insiders19.10% of the stock of Applied Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Applied Therapeutics are expected to grow in the coming year, from ($0.53) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Applied Therapeutics Stock (NASDAQ:APLT)Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More APLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLT Stock News HeadlinesMarch 19, 2024 | insidertrades.comInsider Selling: Applied Therapeutics, Inc. (NASDAQ:APLT) CFO Sells 28,727 Shares of StockMarch 19, 2024 | insidertrades.comApplied Therapeutics, Inc. (NASDAQ:APLT) CEO Shoshana Shendelman Sells 318,573 SharesApril 17, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 15, 2024 | americanbankingnews.comApplied Therapeutics, Inc. (NASDAQ:APLT) Short Interest UpdateApril 15, 2024 | globenewswire.comApplied Therapeutics Appoints Dale Hooks as Chief Commercial OfficerApril 14, 2024 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)April 13, 2024 | americanbankingnews.comApplied Therapeutics (NASDAQ:APLT) Rating Reiterated by Royal Bank of CanadaApril 6, 2024 | investing.comApplied Therapeutics reveals Phase 3 data on heart drugApril 17, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 4, 2024 | finance.yahoo.comApplied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024April 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Applied Therapeutics (APLT) and Vincerx Pharma Inc (VINC)April 1, 2024 | benzinga.comFDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare DiseaseApril 1, 2024 | benzinga.comWhy Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving PremarketMarch 29, 2024 | markets.businessinsider.comApplied Therapeutics Says FDA Extends Review Period Of NDA For GovorestatMarch 28, 2024 | finance.yahoo.comUPDATE 1-US FDA extends review of Applied Therapeutics' genetic disease drugMarch 28, 2024 | reuters.comUS FDA extends review of Applied Therapeutics' genetic disease drugMarch 28, 2024 | globenewswire.comApplied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic GalactosemiaMarch 20, 2024 | investing.comApplied therapeutics CCO sells shares worth over $263kMarch 20, 2024 | investing.comApplied therapeutics CFO sells shares worth over $150kMarch 8, 2024 | finance.yahoo.comApplied Therapeutics Inc (APLT) Announces Year-End 2023 Financial Results and Clinical ProgressMarch 6, 2024 | globenewswire.comApplied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial ResultsMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Applied Therapeutics as FDA Prioritizes Govorestat, Signaling Strong Market ProspectsMarch 1, 2024 | markets.businessinsider.comOptimistic Buy Rating for Applied Therapeutics Amid Favorable Drug Approval Prospects and Strong Financial PositionFebruary 28, 2024 | marketwatch.comApplied Therapeutics Shares Surge on FDA Review, $100 Million Funding RoundFebruary 28, 2024 | markets.businessinsider.comApplied Therapeutics Rallies After Announcing Private Placement Of SharesFebruary 28, 2024 | msn.comFDA Grants Review Date For Applied Therapeutics' First Commercial Product For Rare Metabolic DisorderFebruary 28, 2024 | investorplace.comWhy Is Applied Therapeutics (APLT) Stock Up 59% Today?See More Headlines Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/17/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:APLT CUSIPN/A CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees25Year Founded2017Price Target and Rating Average Stock Price Target$11.60 High Stock Price Target$14.00 Low Stock Price Target$7.00 Potential Upside/Downside+140.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,760,000.00 Net MarginsN/A Pretax Margin-1,198.47% Return on EquityN/A Return on Assets-275.83% Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.76 Sales & Book Value Annual Sales$9.99 million Price / Sales51.20 Cash FlowN/A Price / Cash FlowN/A Book Value($0.20) per share Price / Book-24.15Miscellaneous Outstanding Shares105,890,000Free Float85,663,000Market Cap$511.45 million OptionableOptionable Beta1.81 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Shoshana Shendelman Ph.D. (Age 45)Chair of the Board of Directors, Founder, President, CEO & Secretary Comp: $813.47kMr. Les D. Funtleyder (Age 53)CFO, Principal Financial Officer & Independent Director Comp: $40kDr. Riccardo Perfetti M.D. (Age 63)Ph.D., Chief Medical Officer Comp: $858kMr. Adam Hansard (Age 47)Chief Commercial Officer Comp: $742.66kMr. Constantine Chinoporos (Age 58)COO & Chief Business Officer Ms. Catherine Thorpe (Age 60)Chief Accounting Officer More ExecutivesKey CompetitorsCOMPASS PathwaysNASDAQ:CMPSIGM BiosciencesNASDAQ:IGMSAltimmuneNASDAQ:ALTArriVent BioPharmaNASDAQ:AVBPPhibro Animal HealthNASDAQ:PAHCView All CompetitorsInsiders & InstitutionsShoshana ShendelmanSold 318,573 sharesTotal: $1.72 M ($5.39/share)Riccardo PerfettiSold 110,804 sharesTotal: $597,233.56 ($5.39/share)Leslie D FuntleyderSold 28,727 sharesTotal: $154,838.53 ($5.39/share)Vanguard Group Inc.Bought 1,801,827 shares on 3/11/2024Ownership: 4.183%Goldman Sachs Group Inc.Bought 16,752 shares on 3/1/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions APLT Stock Analysis - Frequently Asked Questions Should I buy or sell Applied Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLT shares. View APLT analyst ratings or view top-rated stocks. What is Applied Therapeutics' stock price target for 2024? 5 analysts have issued twelve-month price targets for Applied Therapeutics' stock. Their APLT share price targets range from $7.00 to $14.00. On average, they expect the company's stock price to reach $11.60 in the next year. This suggests a possible upside of 140.2% from the stock's current price. View analysts price targets for APLT or view top-rated stocks among Wall Street analysts. How have APLT shares performed in 2024? Applied Therapeutics' stock was trading at $3.35 on January 1st, 2024. Since then, APLT shares have increased by 44.2% and is now trading at $4.83. View the best growth stocks for 2024 here. Are investors shorting Applied Therapeutics? Applied Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,980,000 shares, an increase of 31.4% from the March 15th total of 3,790,000 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is presently 2.4 days. View Applied Therapeutics' Short Interest. When is Applied Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our APLT earnings forecast. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics, Inc. (NASDAQ:APLT) posted its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.18. The firm had revenue of ($0.67) million for the quarter. What ETF holds Applied Therapeutics' stock? Simplify Propel Opportunities ETF holds 2,817,505 shares of APLT stock, representing 14.71% of its portfolio. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and RTX (RTX). When did Applied Therapeutics IPO? Applied Therapeutics (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager. How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APLT) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchTop 5 AI Stocks to Buy for 2024Market Moving TrendsOptions trading has suddenly become more reliable.Eagle PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.